Samuraciclib trihydrochloride is primarily used in the field of oncology as a cyclin-dependent kinase (CDK) inhibitor. It is being investigated for its potential to treat various types of cancers, particularly those that are hormone receptor-positive, such as breast cancer. By inhibiting CDK7, this compound disrupts the cell cycle and transcription processes in cancer cells, leading to their growth arrest and apoptosis. Clinical trials are ongoing to evaluate its efficacy and safety as a monotherapy or in combination with other anticancer agents. Its application aims to provide a targeted therapeutic option for patients with resistant or recurrent cancers, offering a potential improvement in treatment outcomes.